Author correction to “Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for NTRK fusion cancers” [Acta Pharmaceutica Sinica B 11 (2021) 355–372]

The authors regret that there are some compound structure errors and misplacement of Ref. Nos. in the article due to the mistake of copying and pasting in the process of assembling figures and negligence in the proofreading. Although it does not affect the conclusion, it is obvious errors. The authors have now modified as below.

The authors apologize for any inconvenience caused to the journal and readers.

• 1. Ref. 23 should be replaced with ‘Cabozantinib in patients with RET fusion-positive advanced non-small cell lung cancer and those with other genotypes: ROS1 or NTRK fusions or increased MET or AXL activity. ClinicalTrails.gov, 2021. Available from: https://clinicaltrials.gov/ct2/show/NCT01639508. Ref. 108 should be replaced with ‘Marx MA, La Greca SD, Chen J, Wessel MD, Arcari JT, inventors. Pfizer Prod Inc., assignee. Preparation of pyrrolopyrimidine derivatives useful in cancer treatment. 2005 Dec 08, WO2005116035A1’. Ref. 110 of compound 39 should be replaced with Ref. 97 on page 365. Ref. 112 of compound 41 should be replaced with Ref. 110 on page 365. Ref. 118 of compound 45 should be replaced with Ref. 117 on page 367; Ref. of 107 for compound 46 should be replaced with ‘Bagal SK, Omoto K, Blakemore DC, Bungay PJ, Bilsland JG, Clarke PJ, et al. Discovery of allosteric, potent, subtype selective and peripherally restricted TRKA kinase inhibitors. J Med Chem 2019;62:247–65’ on page 368.

• 2. Ref. 109 for compound 37 should be replaced with ‘El-Damasy AK, Cho NC, Nam G, Pae AN, Keum G. Discovery of a nanomolar multikinase inhibitor (KST016366): a new benzothiazole derivative with remarkable broad-spectrum antiproliferative activity. Chem Med Chem 2016;11:1587–95’ on page 365. In Fi. 12, the activity of compound 37 (TRKA/B/C IC₅₀ = 1 nmol/L) should be corrected to TRKA IC₅₀ = 3.8 nmol/L, TRKB IC₅₀ = 4.4 nmol/L.

• 3. In Fis. 12 and 14, the activity of compound 40 (TRKA IC₅₀ = 3.8 nmol/L, TRKB IC₅₀ = 4.4 nmol/L) should be corrected to TRKA IC₅₀ = 1.67 nmol/L; the structure of compounds 41 and 45 should be corrected as the following illustration, and the IC₅₀ values of TRKA were 18 and 1.4 nmol/L, respectively.